Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2007
Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Olzowy Bernhard, Canis Martin, Hempel John-Martin, Mazurek Birgit, Suckfüll Markus
Аннотация
OBJECTIVE: To test whether the 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor atorvastatin can slow down the progression of presbycusis.
PATIENTS: Fifty patients 60- to 75-years-old with presbycusis and moderately elevated serum cholesterol.
INTERVENTION(S): In a double-blind design, patients were randomly assigned to treatment with either atorvastatin (40 mg/d orally) or placebo.
MAIN OUTCOME MEASURE(S): Pure-tone audiometry and tinnitus evaluation at enrolment and after 7 and 13 months.
RESULTS: Development of hearing thresholds after 7 and 13 months showed no significant differences between the groups. Tinnitus score continuously improved in the atorvastatin group (34.8 at 7 and 27.6 at 13 mo), whereas it slightly deteriorated in the placebo group (24.8 at 7 and 26.8 at 13 mo). The effect on tinnitus was a tendency without statistic significance (p = 0.0833).
CONCLUSION: Atorvastatin had no effect on the development of hearing thresholds, but resulted in a trend toward a relief of tinnitus.
PATIENTS: Fifty patients 60- to 75-years-old with presbycusis and moderately elevated serum cholesterol.
INTERVENTION(S): In a double-blind design, patients were randomly assigned to treatment with either atorvastatin (40 mg/d orally) or placebo.
MAIN OUTCOME MEASURE(S): Pure-tone audiometry and tinnitus evaluation at enrolment and after 7 and 13 months.
RESULTS: Development of hearing thresholds after 7 and 13 months showed no significant differences between the groups. Tinnitus score continuously improved in the atorvastatin group (34.8 at 7 and 27.6 at 13 mo), whereas it slightly deteriorated in the placebo group (24.8 at 7 and 26.8 at 13 mo). The effect on tinnitus was a tendency without statistic significance (p = 0.0833).
CONCLUSION: Atorvastatin had no effect on the development of hearing thresholds, but resulted in a trend toward a relief of tinnitus.
Предметные рубрики MeSH
AgedAtorvastatinAudiometryAuditory ThresholdCholesterolCholesterol, LDLDisease ProgressionDouble-Blind MethodFemaleHearing Loss, SensorineuralHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPresbycusisProspective StudiesPyrrolesSpeech PerceptionTinnitusTreatment Outcome